Overview

Rivaroxaban Hypericum Trial

Status:
Completed

Trial end date:
2019-04-09

Target enrollment:

Participant gender:

Summary

Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

University Hospital Inselspital, Berne

Collaborator:

Bayer

Treatments:

Rivaroxaban